Physician
Center for Wellness and Pain Care of Las Vegas INC
Center for Wellness and Pain Care of Las Vegas INC was paid $6.49M by Medicaid between Jan 2018 and Dec 2024, across 48 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 56% of everything it billed.
33Billing provider infoCENTER FOR WELLNESS AND PAIN CARE OF LAS VEGAS INC
LAS VEGAS, NV 89113
LAS VEGAS, NV 89113
33aNPI1912387432assigned 06/01/2015
33bProvider typeInterventional Pain Medicine Physician
28Total paid$6.49M
24GClaims186,896
24DCodes billed48
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Interventional Pain Medicine Physician providers in Nevada
Rank by total paid#1 of 13
Median peer was paid$117K
This provider vs. median56×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13,733 | $198K | |
| 2019 | 39,705 | $1.13M | |
| 2020 | 32,263 | $1.37M | |
| 2021 | 30,246 | $1.27M | |
| 2022 | 25,363 | $945K | |
| 2023 | 26,282 | $874K | |
| 2024incomplete | 19,304 | $699K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 56% | 70,779 | 58,058 | $3.66M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 22% | 62,506 | 50,773 | $1.44M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 11% | 9,147 | 7,278 | $688K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.6% | 4,520 | 4,101 | $172K |
| 01992 | 2.0% | 1,478 | 1,174 | $130K | |
| 64483 | 1.4% | 997 | 791 | $91K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 602 | 474 | $54K |
| 99439 | <1% | 1,700 | 1,567 | $41K | |
| 99406 | <1% | 11,453 | 8,762 | $37K | |
| 99205 | Prolong outpt/office vis | <1% | 348 | 282 | $34K |
| 99490 | Ccm add 20min | <1% | 2,289 | 2,004 | $31K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 534 | 386 | $28K |
36 more codes
| 64479 | <1% | 140 | $16K | |
| 64484 | <1% | 380 | $12K | |
| 64493 | <1% | 141 | $11K | |
| 77003 | <1% | 756 | $7K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 64 | $7K |
| 82570 | <1% | 6,966 | $6K | |
| 01991 | <1% | 93 | $6K | |
| 64494 | <1% | 98 | $5K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 92 | $3K |
| 99487 | Ccm add 20min | <1% | 124 | $3K |
| 99489 | Ccm add 20min | <1% | 124 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 41 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 156 | $2K |
| 99457 | <1% | 199 | $1K | |
| 72275 | <1% | 14 | $1K | |
| 99458 | <1% | 122 | $1K | |
| 20553 | <1% | 47 | $731.59 | |
| 64480 | <1% | 15 | $612.10 | |
| 99454 | <1% | 66 | $524.99 | |
| 77002 | <1% | 32 | $436.73 | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 36 | $360.39 |
| J3490 | Unclassified drugs | <1% | 14 | $346.24 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 169 | $247.36 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 36 | $136.39 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 16 | $136.04 |
| 99453 | <1% | 37 | $99.58 | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 23 | $25.25 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 37 | $8.13 |
| G9577 | Patients prescribed opiates for longer than six weeks | 0% | 7,361 | $0.00 |
| G9562 | Patients who had a follow-up evaluation conducted at least every three months during opioid therapy | 0% | 1,158 | $0.00 |
| G9561 | Patients prescribed opiates for longer than six weeks | 0% | 59 | $0.00 |
| G9578 | Documentation of signed opioid treatment agreement at least once during opioid therapy | 0% | 178 | $0.00 |
| G9584 | Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy | 0% | 726 | $0.00 |
| 99000 | 0% | 858 | $0.00 | |
| 1034F | 0% | 146 | $0.00 | |
| G9583 | Patients prescribed opiates for longer than six weeks | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCAMPBELL, NEVILLE (SECRETARY/TREASURER)